

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 6**Complete if Known**

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Art Unit	1617
Examiner Name	Deirdre R. Claytor
Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2,665,277	01-05-1954	Homeyer <i>et al.</i>	All
	U2	US-3,970,651	07-20-1976	Kaplan <i>et al.</i>	All
	U3	US-4,925,674	05-15-1990	Giannini <i>et al.</i>	All
	U4	US-4,927,855	05-22-1990	Lafon	All
	U5	US-4,994,604	02-19-1991	Tung <i>et al.</i>	All
	U6	US-5,023,092	06-11-1991	DuRoss	All
	U7	US-5,521,207	05-28-1996	Graneto	All
	U8	US-5,273,760	12-28-1993	Oshlack <i>et al.</i>	All
	U9	US-5,286,493	02-15-1994	Oshlack <i>et al.</i>	All
	U10	US-5,324,351	06-28-1994	Oshlack <i>et al.</i>	All
	U11	US-5,356,467	10-18-1994	Oshlack <i>et al.</i>	All
	U12	US-5,366,738	11-22-1994	Rork <i>et al.</i>	All
	U13	US-5,472,712	12-05-1995	Oshlack <i>et al.</i>	All
	U14	US-5,510,496	04-23-1996	Talley <i>et al.</i>	All
	U15	US-5,563,165	10-08-1996	Talley <i>et al.</i>	All
	U16	US-5,631,250	05-20-1997	Bunnell <i>et al.</i>	All
	U17	US-5,633,272	05-27-1997	Talley <i>et al.</i>	All
	U18	US-5,703,232	12-30-1997	Bunnell <i>et al.</i>	All
	U19	US-5,736,541	04-07-1998	Bunnell <i>et al.</i>	All
	U20	US-5,753,688	05-19-1998	Talley <i>et al.</i>	All
	U21	US-5,760,068	06-02-1998	Talley <i>et al.</i>	All
	U22	US-5,932,598	08-03-1999	Talley <i>et al.</i>	All

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Art Unit	1617
Examiner Name	Deirdre R. Claytor
Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U23	US-5,972,986	10-26-1999	Seibert <i>et al.</i>	All
	U24	US-5,985,902	11-16-1999	Talley <i>et al.</i>	All
	U25	US-6,054,136	04-25-2000	Farah <i>et al.</i>	All
	U26	US-6,132,420	10-17-2000	Dionne <i>et al.</i>	All
	U27	US-6,156,781	12-05-2000	Talley <i>et al.</i>	All
	U28	US-6,245,357	06-12-2001	Edgren <i>et al.</i>	All
	U29	US-6,270,787	08-07-2001	Ayer	All
	U30	US-6,283,953	09-04-2001	Ayer <i>et al.</i>	All
	U31	US-6,287,295	09-11-2001	Chen <i>et al.</i>	All
	U32	US-6,323,266	11-27-2001	Phillips	All
	U33	US-6,333,050	12-25-2001	Wong <i>et al.</i>	All
	U34	US-6,342,249	01-29-2002	Wong <i>et al.</i>	All
	U35	US-6,348,458	02-19-2002	Hamied <i>et al.</i>	All
	U36	US-6,365,185	04-02-2002	Ritschel <i>et al.</i>	All
	U37	US-6,368,626	04-09-2002	Bhatt <i>et al.</i>	All
	U38	US-6,375,978	04-23-2002	Kleiner <i>et al.</i>	All
	U39	US-6,384,034	05-07-2002	Smitchieva <i>et al.</i>	All
	U40	US-6,403,640	06-11-2002	Stoner <i>et al.</i>	All
	U41	US-6,413,965	07-02-2002	Mylari	All
	U42	US-6,420,394	07-16-2002	Supersaxo	All
	U43	US-6,579,895	06-17-2003	Karim <i>et al.</i>	All
	U44	US-6,613,790	09-02-2003	Carter	All

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard 1.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Art Unit	1617
Examiner Name	Deirdre R. Claytor
Attorney Docket Number	TPI.350C1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U45	US-7,172,769	02-06-2007	Kararli <i>et al.</i>	All
	U46	US-7,205,413	04-17-2007	Morissette <i>et al.</i>	All
	U47	US-7,446,107	11-04-2008	Remenar <i>et al.</i>	All
	U48	US-7,452,555	11-18-2008	Childs	All
	U49	US-7,459,449	12-02-2008	Keltjens	All
	U50	US-2002/0013357	01-31-2002	Nadkarni <i>et al.</i>	All
	U51	US-2002/0006951	01-17-2002	Hageman <i>et al.</i>	All
	U52	US-2002/0015735	02-07-2002	Hedden <i>et al.</i>	All
	U53	US-2002/0034542	03-21-2002	Thombre <i>et al.</i>	All
	U54	US-2002/0071857	06-13-2002	Kararli <i>et al.</i>	All
	U55	US-2002/0107250	08-08-2002	Hariharan <i>et al.</i>	All
	U56	US-2002/0119193	08-29-2002	Le <i>et al.</i>	All
	U57	US-2004/0029946	02-12-2004	Arora <i>et al.</i>	All
	U58	US-2004/0154890	08-12-2004	Liu	All
	U59	US-2004/0242640	12-02-2004	Desai <i>et al.</i>	All
	U60	US-2005/0070551	03-31-2005	Remenar <i>et al.</i>	All
	U61	US-2007/0015841	01-18-2007	Tawa <i>et al.</i>	All
	U62	US-2007/0293674	12-20-2007	Scoppettuolo <i>et al.</i>	All
	U63	US-7,132,570	11-07-2006	Neckebroek <i>et al.</i>	All
	U64	US-			
	U65	US-			
	U66	US-			

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing this form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

4

of

6

Complete if Known

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Group Art Unit	1617
Examiner Name	Deirdre R. Claytor
Attorney Docket Number	TPI 350C1

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 01/45706	06-28-2001	Pharmacia Corporation	All	
	F2	WO 2002/102376	12-27-2002	Pharmacia Corporation	All	
	F3	WO 2002/10125	02-07-2002	Teva Pharmaceutical Industries Ltd.	All	
	F4	WO 2002/056915	07-25-2002	Cephalon, Inc.	All	
	F5	WO 2005/053612	06-16-2005	Shire Laboratories, Inc.	All	
	F6	WO 96/33193	10-24-1996	Janssen Pharmaceutica N.V.	All	
	F7	JP 54-095589	07-28-1979	Sumitomo Chemical Co. Ltd.	All	
	F8	FR 2,849,029	06-25-2004	Laboratoire L. Lafon	All	

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	BALL, P. "Scandal of crystal design..." <i>Nature</i> , June 20, 1996, pp. 648-650, Vol. 381.	
	R2	BASTIN, R. J. <i>et al.</i> "Salt Selection and Optimization Procedures for Pharmaceutical New Chemical Entities" <i>Organic Process Research & Development</i> , 2000, pp. 427-435, Vol. 4, No. 5.	
	R3	BERNSTEIN, J. <i>et al.</i> "Concomitant Polymorphs" <i>Angew. Chem. Int. Ed.</i> , 1999, pp. 3440-3461, Vol. 38.	
	R4	BOUCHER, E. <i>et al.</i> "Use of Hydrogen Bonds to Control Molecular Aggregation. Behavior of Dipyridones and Pyridone-Pyrimidones Designed to Form Cyclic Triplexes" <i>J. Org. Chem.</i> , 1995, pp. 1408-1412, Vol. 60.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 5 of 6**Complete if Known**

Application Number	10/660,202
Filing Date	September 11, 2003
First Named Inventor	Örn Almarsson
Group Art Unit	1627
Examiner Name	Deirdre R. Claytor
Attorney Docket Number	TPI 350C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R5	BRITTAI, H. G. "Polymorphism in Pharmaceutical Solids, Marcel Dekker, Inc., 1999, pp. 183, 202-208 and 219.	
	R6	CHANG, Y. et al. "An Approach to the Design of Molecular Solids. Strategies for Controlling the Assembly of Molecules into Two-Dimensional Layered Structures" <i>J. Am. Chem. Soc.</i> , 1993, pp. 5991-6000, Vol. 115.	
	R7	COWAN, J. A. et al. "Neutron diffraction studies of the 1:1 and 2:1 cocrystals of benzene-1,2,4,5-tetracarboxylic acid and 4,4'-bipyridine" <i>Acta Cryst.</i> , 2006, pp. o157-o161, Vol. C62.	
	R8	DAVIDOVICH, M. et al. "Detection of Polymorphism by Powder X-Ray Diffraction: Interference by Preferred Orientation" <i>American Pharmaceutical Review</i> , 2004, pp. 10, 12, 14, 16, and 100, Vol. 7, Issue 1.	
	R9	DAVIES, N. M. et al. "Clinical Pharmacokinetics and Pharmacodynamics of Celecoxib. A Selective Cyclo-Oxygenase-2 Inhibitor" <i>Clin. Pharmacokin.</i> , March 2000, pp. 225-242, Vol. 38, No. 3.	
	R10	DEAN, J. A., <i>Analytical Chemistry Handbook</i> , McGraw-Hill, Inc., 1995, pp. 10.24-10.26.	
	R11	Definition of solvate, The Free Dictionary, http://www.thefreedictionary.com/solvate , accessed online on 21 July 2009, pp. 1-3.	
	R12	DESIRAJU, G. R. "Solid-State Chemistry: Crystal Gazing: Structure Prediction and Polymorphism" <i>Science</i> , October 17, 1997, pp. 404-405, Vol. 278, No. 5337.	
	R13	DOELKER, E. "Physicochemical behavior of active substances. Consequences for the feasibility and stability of pharmaceutical forms" <i>STP Pharma Pratiques</i> , 1999, pp. 399-409, Vol. 9, No.5.	
	R14	DOELKER, E. "Crystalline modifications and polymorphism changes during drug manufacturing" <i>Annales Pharmaceutiques Francaises</i> , 2002, pp. 161-176, Vol. 60, No. 3.	
	R15	DUNITZ, J. D. "Are crystal structures predictable?" <i>Chem Commun.</i> , 2003, pp. 545-548.	
	R16	FEYNMAN, R. P. "There's Plenty of Room at the Bottom" <i>Engineering and Science</i> , February 1960, pp. 22-36.	
	R17	JAIN, N. K. et al. "Polymorphism in Pharmacy" <i>Indian Drugs</i> , 1986, pp. 315-329, Vol. 23, No. 6.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

Application Number 10/660,202
Filing Date September 11, 2003
First Named Inventor Örn Almarsson
Group Art Unit 1617
Examiner Name Deirdre R. Claylor
Attorney Docket Number TPI 350C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No., ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	R18	KIRCHNER, M. T. <i>et al.</i> , Co-crystals with Acetylene: Small is not Simple" <i>Chem. Eur. J.</i> , 2010, pp. 2131-2146, Vol. 16.	
	R19	MOULTON, B. <i>et al.</i> "From Molecules to Crystal Engineering: Supramolecular Isomerism and Polymorphism in Network Solids" <i>Chem. Rev.</i> , 2001, pp. 1629-1658, Vol. 101.	
	R20	MUZAFFAR, N. A. <i>et al.</i> "Polymorphism and Drug Availability" <i>Journal of Pharmacy</i> , 1979, pp. 59-66, Vol. 1, No. 1.	
	R21	OSORIO-LOZADA, A. <i>et al.</i> "Synthesis and determination of the absolute stereochemistry of the enantiomers of adrafinil and modafinil" <i>Tetrahedron: Asymmetry</i> , 2004, pp. 3811-3815, Vol. 15.	
	R22	OTSUKA, M. <i>et al.</i> "Effect of Polymorphic Forms of Bulk Powders on Pharmaceutical Properties of Carbamazepine Granules" <i>Chem. Pharm. Bull.</i> , 1999, pp. 852-856, Vol. 47, No. 6.	
	R23	SHATTOCK, T. R. <i>et al.</i> "Hierarchy of Supramolecular Synths: Persistent Carboxylic Acid-Pyridine Hydrogen Bonds in Cocrystals That also Contain a Hydroxyl Moiety" <i>Cryst. Growth Des.</i> , 2008, pp. 4533-4545, Vol. 8, No. 12.	
	R24	THAYER, A. M. "Form and Function: The choice of pharmaceutical crystalline form can be used to optimize drug properties, and cocrystals are emerging as new alternatives" <i>Chemical & Engineering News</i> , June 18, 2007, pp. 17-30, Vol. 85, No. 25.	
	R25	U.S. Pharmacopia #23, 1995, p. 1843.	
	R26	VILLA, L. A. <i>et al.</i> "Central Nervous System Paracoccidioidomycosis. Report of a Case Successfully Treated with Itraconazol" <i>Rev. Inst. Med. Trop. S. Paulo</i> , July-August 2000, pp. 231-234, Vol. 42, No. 4.	
	R27	ZAWOROTKO, M. J. "Crystal Engineering of Diamondoid Networks" <i>Chemical Society Reviews</i> , 1994, pp. 283-288, Vol. 23.	
	R28	KLEIN, C. L. <i>et al.</i> "Molecular Structure of Two Conformationally Restrained Fentanyl Analogues: cis- and trans-Isomers of N-[3-Methyl-1-[2-(1,2,3,4-tetrahydronaphthyl)-4-piperidinyl]-N-phenylpropanamide" <i>Journal of Pharmaceutical Sciences</i> , November 1985, pp. 1147-1151, Vol. 74, No. 11.	
	R29		

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2